225 related articles for article (PubMed ID: 28734147)
1. Rapid response of metastatic cutaneous squamous cell carcinoma to pembrolizumab in a patient with xeroderma pigmentosum: Case report and review of the literature.
Deinlein T; Lax SF; Schwarz T; Giuffrida R; Schmid-Zalaudek K; Zalaudek I
Eur J Cancer; 2017 Sep; 83():99-102. PubMed ID: 28734147
[No Abstract] [Full Text] [Related]
2. Regression of melanoma metastases and multiple non-melanoma skin cancers in xeroderma pigmentosum by the PD1-antibody pembrolizumab.
Hauschild A; Eichstaedt J; Möbus L; Kähler K; Weichenthal M; Schwarz T; Weidinger S
Eur J Cancer; 2017 May; 77():84-87. PubMed ID: 28365530
[No Abstract] [Full Text] [Related]
3. Efficacy of pembrolizumab in a patient with xeroderma pigmentosum variant and advanced cutaneous squamous-cell carcinoma.
Hennemann A; Collonge Rame MA; Puzenat E; Ged C; Harbon S; Aubin F; Nardin C
Acta Oncol; 2022 Sep; 61(9):1140-1142. PubMed ID: 35950634
[No Abstract] [Full Text] [Related]
4. Clinical remission of xeroderma pigmentosum-associated squamous cell carcinoma with isotretinoin and chemotherapy: case report.
Saade M; Debahy NE; Houjeily S
J Chemother; 1999 Aug; 11(4):313-7. PubMed ID: 10465136
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapeutic strategies for cutaneous squamous cell carcinoma prevention in xeroderma pigmentosum.
Ameri AH; Mooradian MJ; Emerick KS; Park JC; Wirth LJ; Asgari MM; Tsao H; Lawrence D; Sullivan RJ; Demehri S
Br J Dermatol; 2019 Nov; 181(5):1095-1097. PubMed ID: 31102460
[No Abstract] [Full Text] [Related]
6. Dramatic response to nivolumab in xeroderma pigmentosum skin tumor.
Chambon F; Osdoit S; Bagny K; Moro A; Nguyen J; Réguerre Y
Pediatr Blood Cancer; 2018 Feb; 65(2):. PubMed ID: 28988442
[TBL] [Abstract][Full Text] [Related]
7. A Case Report of Unresectable Cutaneous Squamous Cell Carcinoma Responsive to Pembrolizumab, a Programmed Cell Death Protein 1 Inhibitor.
Chang AL; Kim J; Luciano R; Sullivan-Chang L; Colevas AD
JAMA Dermatol; 2016 Jan; 152(1):106-8. PubMed ID: 26422398
[No Abstract] [Full Text] [Related]
8. Xeroderma pigmentosum: neck lymph node metastasis of a squamous cell carcinoma of the skin treated with cetuximab.
Rubió Casadevall J; Graña-Suárez B; Hernandez-Yagüe X; Vayreda Ribera J; Huc Grasa O; Brunet Vidal J
Eur J Dermatol; 2009; 19(2):163-5. PubMed ID: 19106040
[TBL] [Abstract][Full Text] [Related]
9. Patterns of response and acquired resistance to the programmed death-1 inhibitor pembrolizumab in Stage III metastatic cutaneous squamous cell carcinoma.
Zalaudek I; Corneli P; Vernoni S; Fedele D; Papa G; Conforti C; Retrosi C; Vezzoni R; Fagotti S; Longone M; Farinazzo E; di Meo N; Pizzichetta MA
Dermatol Ther; 2019 Nov; 32(6):e13107. PubMed ID: 31595596
[No Abstract] [Full Text] [Related]
10. Comparison of the clinical and histological effects of 5-fluorouracil (5-FU) alone and of 5-FU preceded by dimethyl-sulphoxide (DMSO) on senile keratosis.
Garcia-Perez A; Aparicio M; Carapeto FJ
Dermatologica; 1970; 140():Suppl 1:119+. PubMed ID: 5471357
[No Abstract] [Full Text] [Related]
11. Treatment of cancer in a child with ocular xeroderma pigmentosa (XP) in Malawi.
Schulze Schwering M; Chagaluka G; Molyneux E
J Pediatr Hematol Oncol; 2014 Nov; 36(8):e540-2. PubMed ID: 24390455
[TBL] [Abstract][Full Text] [Related]
12. Clinical Response With Pembrolizumab for Cutaneous Squamous Cell Carcinoma.
Corbett M; Tohani S; Ramli R; O'Duffy F
JAMA Otolaryngol Head Neck Surg; 2024 Jun; 150(6):524-525. PubMed ID: 38602669
[TBL] [Abstract][Full Text] [Related]
13. Prolonged Response to Pembrolizumab in Spindle Cell Squamous Cell Carcinoma Metastatic to the Central Nervous System.
Liu Y; Fitzgerald B; Perry E; Pathak A; Chao HH
J Investig Med High Impact Case Rep; 2019; 7():2324709619850216. PubMed ID: 31132886
[TBL] [Abstract][Full Text] [Related]
14. Bleomycin in xeroderma pigmentosum.
Short J; Price RA; Pratt CB
Cancer; 1973 Feb; 31(2):449-54. PubMed ID: 4120025
[No Abstract] [Full Text] [Related]
15. Xeroderma pigmentosum variant or pigmented xerodermoid.
Somos S; Schneider I; Raskó I
Anticancer Res; 1997; 17(1B):753-6. PubMed ID: 9066615
[TBL] [Abstract][Full Text] [Related]
16. Multiple cutaneous malignancies in a patient of xeroderma pigmentosum.
Grampurohit VU; Dinesh US; Rao R
J Cancer Res Ther; 2011; 7(2):205-7. PubMed ID: 21768716
[TBL] [Abstract][Full Text] [Related]
17. Follow-up on Programmed Cell Death 1 Inhibitor for Cutaneous Squamous Cell Carcinoma.
Tran DC; Colevas AD; Chang AL
JAMA Dermatol; 2017 Jan; 153(1):92-94. PubMed ID: 27784038
[No Abstract] [Full Text] [Related]
18. [Xeroderma pigmentosum: report of 6 cases in Dakar].
Dieng MT; Niang SO; Dangou JM; Ndiaye B
Bull Cancer; 2001 Feb; 88(2):199-202. PubMed ID: 11257594
[TBL] [Abstract][Full Text] [Related]
19. Treatment of unresectable cutaneous squamous cell carcinoma with pembrolizumab.
Venkatesh S; Al-Haseni A; Sahni D
BMJ Case Rep; 2019 Aug; 12(8):. PubMed ID: 31377718
[TBL] [Abstract][Full Text] [Related]
20. Multiple melanomas occurring in a patient with xeroderma pigmentosum.
Tullis GD; Lynde CW; McLean DI; Stewart WD
J Am Acad Dermatol; 1984 Aug; 11(2 Pt 2):364-7. PubMed ID: 6480943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
